LifeSci Advisors in collaboration with Westmount Capital are bringing for the third to Milano Protalix Biotherapeutics, a biopharmaceutical company focused on the development, production, and commercialization of innovative medicines for patients living with rare diseases

 

LifeSci Advisors in collaboration with Westmount Capital are pleased to bring to Milano for the third time Protalix Biotherapeutics, a biopharmaceutical company focused on the development, production, and commercialization of innovative medicines for patients living with rare diseases.

We are advancing promising candidates leveraging our expertise in protein therapeutics through our proprietary, commercial-scale ProCellEx^® plant cell-based protein expression system, as well as our chemical and genetic modification capabilities, including PEGylation. With two approved drugs already making an impact, we are committed to expanding our pipeline to address the unmet needs of patients facing some of the most challenging rare diseases.

(NYSE:PLX) $1.25 on November 1^st, 2024

73,54 Million shares issued & outstanding

Market Cap = US$91.9 Million; 

Summary: Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. It is the first company to gain U.S. Food and Drug Administration (FDA) approval of a protein produced through plant cell-based in suspension expression system. 

This unique expression system represents a new method for developing recombinant proteins in an industrial-scale manner. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights to taliglucerase alfa for the treatment of Gaucher disease, Protalix’s first product manufactured through ProCellEx, excluding in Brazil, where Protalix retains full rights. Protalix’s second product, Elfabrio^®, was approved by both the FDA and the European Medicines Agency in May 2023.

Protalix has partnered with Chiesi Farmaceutici S.p.A. for the global development and commercialization of Elfabrio.

Protalix’s development pipeline consists of proprietary versions of recombinant therapeutic proteins that target established pharmaceutical markets, including the following product candidates: PRX–115, a plant cell-expressed recombinant PEGylated uricase for the treatment of severe gout; PRX–119, a plant cell-expressed long action DNase I for the treatment of NETs-related diseases; and others.

Why meet Protalix now? Here are five good reasons to consider buying Protalix Biotherapeutics stock:

1. **Pipeline of promising products**: Protalix Biotherapeutics develops innovative treatments for various rare diseases. Their pipeline of products under development could offer significant growth potential if these treatments gain regulatory approval.

2. **Unique Technology**: The company uses a plant cell-based production platform, which could reduce manufacturing costs and provide high-quality biologicals. This differentiated approach could give Protalix a competitive advantage in the market.

3. **Strategic Partnerships**: Protalix collaborates with other companies and institutions, which can provide additional resources, expertise and financial support. These partnerships can also facilitate the development and marketing of their products.

4. **Expanding market**: Drugs for rare diseases are experiencing growing demand. By targeting specific, less competitive market segments, Protalix could benefit from significant sales opportunities.

5. **Capital Appreciation Potential**: If Protalix’s products succeed in clinical trials and are ultimately commercialized, this could result in a significant increase in the value of the company’s stock, providing an opportunity for appreciation capital for investors.

It is important to do thorough research and assess risks before making any investment decision.

care of the redaction

please follow us also with a like on Instagram, user name: gio.vanni.acerbi